MA31367B1 - Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson. - Google Patents

Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.

Info

Publication number
MA31367B1
MA31367B1 MA32333A MA32333A MA31367B1 MA 31367 B1 MA31367 B1 MA 31367B1 MA 32333 A MA32333 A MA 32333A MA 32333 A MA32333 A MA 32333A MA 31367 B1 MA31367 B1 MA 31367B1
Authority
MA
Morocco
Prior art keywords
pyridine
carboxamide
parkinson
dichloro
disease
Prior art date
Application number
MA32333A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31367B1 publication Critical patent/MA31367B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA32333A 2007-04-19 2009-11-10 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson. MA31367B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
MA31367B1 true MA31367B1 (fr) 2010-05-03

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32333A MA31367B1 (fr) 2007-04-19 2009-11-10 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.

Country Status (33)

Country Link
US (1) US20100130554A1 (cg-RX-API-DMAC7.html)
EP (1) EP2146714B1 (cg-RX-API-DMAC7.html)
JP (1) JP5386478B2 (cg-RX-API-DMAC7.html)
KR (2) KR101503942B1 (cg-RX-API-DMAC7.html)
CN (1) CN101663035B (cg-RX-API-DMAC7.html)
AR (1) AR066108A1 (cg-RX-API-DMAC7.html)
AT (1) ATE513548T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008257322B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810444A2 (cg-RX-API-DMAC7.html)
CA (1) CA2684174C (cg-RX-API-DMAC7.html)
CL (1) CL2008001136A1 (cg-RX-API-DMAC7.html)
CY (1) CY1111840T1 (cg-RX-API-DMAC7.html)
DK (1) DK2146714T3 (cg-RX-API-DMAC7.html)
EA (1) EA019194B1 (cg-RX-API-DMAC7.html)
ES (1) ES2367408T3 (cg-RX-API-DMAC7.html)
FR (1) FR2915100B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20110666T1 (cg-RX-API-DMAC7.html)
IL (1) IL201448A (cg-RX-API-DMAC7.html)
JO (1) JO2678B1 (cg-RX-API-DMAC7.html)
MA (1) MA31367B1 (cg-RX-API-DMAC7.html)
ME (1) ME00935B (cg-RX-API-DMAC7.html)
MX (1) MX2009011284A (cg-RX-API-DMAC7.html)
MY (1) MY148092A (cg-RX-API-DMAC7.html)
NZ (1) NZ580482A (cg-RX-API-DMAC7.html)
PA (1) PA8776801A1 (cg-RX-API-DMAC7.html)
PL (1) PL2146714T3 (cg-RX-API-DMAC7.html)
PT (1) PT2146714E (cg-RX-API-DMAC7.html)
RS (1) RS51869B (cg-RX-API-DMAC7.html)
SI (1) SI2146714T1 (cg-RX-API-DMAC7.html)
TW (1) TWI439269B (cg-RX-API-DMAC7.html)
UY (1) UY31035A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008145841A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907251B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150087252A (ko) * 2012-11-28 2015-07-29 사노피 4-(사이클로프로필메톡시)-n-(3,5-디클로로-1-옥시도피리딘-4-일)-5-메톡시피리딘-2-카복스아미드의 결정 형태의 제조 방법 및 이의 결정 형태
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DK0711282T3 (da) * 1993-07-28 2002-09-16 Aventis Pharma Ltd Forbindelser som PDE IV og TNF inhibitorer
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) * 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンpde4阻害剤
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
ES2367408T3 (es) 2011-11-03
ME00935B (me) 2012-06-20
CA2684174A1 (fr) 2008-12-04
MX2009011284A (es) 2009-11-02
JP5386478B2 (ja) 2014-01-15
ATE513548T1 (de) 2011-07-15
EP2146714A1 (fr) 2010-01-27
EA019194B1 (ru) 2014-01-30
CL2008001136A1 (es) 2009-01-16
SI2146714T1 (sl) 2011-10-28
ZA200907251B (en) 2011-04-28
RS51869B (sr) 2012-02-29
CA2684174C (fr) 2014-02-25
EA200970970A1 (ru) 2010-02-26
KR20090130059A (ko) 2009-12-17
IL201448A (en) 2014-08-31
CN101663035A (zh) 2010-03-03
HRP20110666T1 (hr) 2011-10-31
FR2915100B1 (fr) 2009-06-05
UY31035A1 (es) 2008-11-28
FR2915100A1 (fr) 2008-10-24
HK1141725A1 (en) 2010-11-19
WO2008145841A1 (fr) 2008-12-04
KR20150004885A (ko) 2015-01-13
JO2678B1 (en) 2013-03-03
TWI439269B (zh) 2014-06-01
TW200911247A (en) 2009-03-16
EP2146714B1 (fr) 2011-06-22
CY1111840T1 (el) 2015-10-07
US20100130554A1 (en) 2010-05-27
AU2008257322B2 (en) 2013-06-13
JP2010524906A (ja) 2010-07-22
CN101663035B (zh) 2012-06-20
KR101503942B1 (ko) 2015-03-18
PA8776801A1 (es) 2008-11-19
AU2008257322A1 (en) 2008-12-04
AR066108A1 (es) 2009-07-22
PT2146714E (pt) 2011-09-02
NZ580482A (en) 2011-10-28
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
MY148092A (en) 2013-02-28
PL2146714T3 (pl) 2011-10-31
IL201448A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
EP2063889A4 (en) SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA30632B1 (fr) Anticorps humanisé
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
FR2915398B1 (fr) "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP2683382A4 (en) DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY
MA30514B1 (fr) Nouveaux composes.
MA32506B1 (fr) Nouveaux composes
MA31798B1 (fr) Composés organiques
MA31198B1 (fr) Nouvelle forme dosifiee
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
MA31367B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
DK1786442T3 (da) Behandling af neurodegenerative sygdomme under anvendelse af DEGS-inhibitorer
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
MA31369B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
EP2213290A4 (en) MEANS FOR IMPROVING MOTOR COMPLICATIONS OR PSYCHIATRIC SYMPTOMS AT MORBUS PARKINSON
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire
EP2219447A4 (en) S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF UTERUS HYPERCONTACTILITY DISORDERS
EP1889618A4 (en) Combined drug for treating diabetes